mAbs (Jan 2021)

An efficient system for bioconjugation based on a widely applicable engineered O-glycosylation tag <subtitle>Short title: Controlled bioconjugation via O-glycan engineering</subtitle>

  • Thomas V. Murray,
  • Kasia Kozakowska-McDonnell,
  • Adam Tibbles,
  • Annabel Taylor,
  • Daniel Higazi,
  • Emmanuel Rossy,
  • Alessandra Rossi,
  • Sivaneswary Genapathy,
  • Giulia Tamburrino,
  • Nicola Rath,
  • Natalie Tigue,
  • Vivian Lindo,
  • Tristan Vaughan,
  • Monika A. Papworth

DOI
https://doi.org/10.1080/19420862.2021.1992068
Journal volume & issue
Vol. 13, no. 1

Abstract

Read online

Bioconjugates are an important class of therapeutic molecules. To date, O-glycan-based metabolic glycoengineering has had limited use in this field, due to the complexities of the endogenous O-glycosylation pathway and the lack of an O-glycosylation consensus sequence. Here, we describe the development of a versatile on-demand O-glycosylation system that uses a novel, widely applicable 5 amino acid O-glycosylation tag, and a metabolically engineered UDP-galactose-4-eperimase (GALE) knock-out cell line. Optimization of the primary sequence of the tag enables the production of Fc-based proteins with either single or multiple O-glycans with complexity fully controlled by media supplementation. We demonstrate how the uniformly labeled proteins containing exclusively N-azido-acetylgalactosamine are used for CLICK chemistry-based bioconjugation to generate site-specifically fluorochrome-labeled antibodies, dual-payload molecules, and bioactive Fc-peptides for applications in basic research and drug discovery. To our knowledge, this is the first description of generating a site-specific O-glycosylation system by combining an O-glycosylation tag and a metabolically engineered cell line.

Keywords